BioWorld Today: News to Note - Lithera, Inc.

March 05, 2013 - BioWorld Today

Lithera Inc., of San Diego, said the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase IIb RESET study. LIPO-202, Lithera’s lead product candidate, is an injectable pharmaceutical product designed to produce local, selective fat tissue reduction. The trial will measure the effects of three different doses of LIPO-202, compared to placebo, on abdominal bulging due to excess subcutaneous fat in healthy, nonobese subjects. Patients randomized into each of the four study arms will receive subcutaneous injections spaced evenly across the abdomen once per week for eight weeks. Study endpoints include multiple qualitative and quantitative measures of bulge reduction, as well as key safety information. Topline data readout is expected in the third quarter.